Burnett Patrick's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Dec 31, 2024
- Accession no.
- 0001787306-24-000174
- Filed
- Dec 31, 2024
- Trade date
- Dec 31, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $23.7K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Burnett PatrickCIK 0001741987 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | Common Stock | SSaleDisposed | −1,691 | $14.00F2 | −$23,674 | 126,978 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.8068 to $14.40, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Reporting Person's title: Executive Vice President, Chief Medical Officer